Navigation Links
iPierian Appoints Dr. Chad Cowan and Dr. Konrad Hochedlinger to Scientific Advisory Board
Date:8/6/2009

SOUTH SAN FRANCISCO, Calif., Aug. 6 /PRNewswire/ -- iPierian, Inc., a biopharmaceutical company focused on changing the paradigm of drug discovery and development through the application of cellular reprogramming, today announced the appointments of Dr. Chad Cowan and Dr. Konrad Hochedlinger to the company's Scientific Advisory Board (SAB).

"Drs. Cowan and Hochedlinger are leading scientists in stem cell research and their addition to the iPierian SAB rounds out an exemplary group of scientists. The collective expertise of this SAB will further our efforts of developing disease-relevant models to discover drugs, and translating these efforts into new therapies for patients," said John P. Walker, chief executive officer of iPierian.

Dr. Chad Cowan is assistant professor of Medicine at Harvard Medical School and the Department of Stem Cell and Regenerative Biology, and assistant investigator at Stowers Medical Institute. His research focuses on adipogenesis, metabolic disease, and the impact of environmental and genetic factors on the development of disease.

Dr. Konrad Hochedlinger is assistant professor of Medicine at Harvard Medical School and the Department of Stem Cell and Regenerative Biology, principal faculty member at the Harvard Stem Cell Institute and investigator at the Massachusetts General Hospital Cancer Center and Center for Regenerative Medicine. Dr. Hochedlinger is a leader in reprogramming technology and produced the first transgene-free induced pluripotent stem (iPS) cells. Most recently, Dr. Hochedlinger received the International Society for Stem Cell Research (ISSCR) Outstanding Young Investigator Award.

About iPierian

iPierian is a South San Francisco-based biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPS) technology with the mission of creating new therapeutics through cellular reprogramming and directed differentiation of patient cells. iPierian is backed by Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital and FinTech Global Capital. The initial focus of the company is in neurodegeneration, particularly spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and Parkinson's disease as well as in cardiovascular disease, where iPierian has a collaboration with The Gladstone Institute of Cardiovascular Disease and Dr. Deepak Srivastava, the institute's director. iPierian plans to enhance its partnership efforts to further expand into metabolic diseases. Earlier this year, the company announced a formal collaboration with the laboratory of Dr. Shinya Yamanaka of Kyoto University to develop and improve methods of deriving iPS cell lines in order to advance iPS cell technology.

Because iPS cells are believed to be able to grow indefinitely in culture and to differentiate into many cell types, iPS cells have great potential for disease research, preclinical drug testing and cell-based therapy. iPierian's approach places the patient at the forefront of the drug discovery process in order to reduce drug development time and increase the probability of success for drug candidates. iPierian plans to use precise human disease models to find new molecular targets and develop proprietary therapeutic small molecule or biologic drugs for its own pipeline to treat specific diseases.


'/>"/>
SOURCE iPierian, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Streamline Health Appoints Jon Phillips Chairman of the Board of Directors
2. Novo Nordisk Appoints Per Falk, M.D., Ph.D., as Vice President for Clinical, Medical and Regulatory Affairs for North America
3. Excaliard Pharmaceuticals Appoints Jay Birnbaum, Ph.D. to the Board of Directors.
4. Globaltel Media Appoints Leading Healthcare Industry Veterans to Advisory Board
5. Sunesis Pharmaceuticals Appoints Helen S. Kim to Board of Directors
6. Red Cross Appoints Peggy Dyer as Chief Marketing Officer
7. MonoSol Rx Appoints Theodore Clemente Vice President Business Development
8. WuXi PharmaTech Appoints Dr. Chi-Chung Chan as Vice President of Pharmacology
9. Webmedx Appoints New Senior Vice President of Client Development, Chris Cashwell
10. Immucor Appoints Chief Operating Officer
11. DaVita Clinical Research Appoints Mahesh Krishnan as Vice President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... , ... May 06, 2016 , ... ... online provider of career-focused education and corporate training, and the National Military Family ... to announce Maritza Aquino as the second full-tuition scholarship recipient of 2016. ...
(Date:5/6/2016)... Opelousas, LA (PRWEB) , ... May 06, 2016 ... ... General Health System and David Konur, CEO of Cardiovascular Institute of the South ... South will be performing a live case of an Intravascular Ultrasound Guided Coronary ...
(Date:5/6/2016)... ... May 06, 2016 , ... RowdMap, Inc. co-founder, Joshua Rosenthal, ... Former Principal Deputy Administrator at Centers for Medicare and Medicaid Services (CMS); Ali ... Chief Medical Officer at Health Care Service Corporation (Blue Cross and Blue Shield ...
(Date:5/5/2016)... ... May 05, 2016 , ... While the practice and profession of Aging ... our aging population has on communities and resources. Aging Life Care plays an important ... age-related challenges. , Aging Life Care is a holistic, client-centered approach to caring ...
(Date:5/5/2016)... ... May 05, 2016 , ... Qrono ... today announced a development collaboration with the Australian critical medicine company, Phebra ... as schizophrenia. , LAI medicines can offer improved therapeutic benefits over oral formulations, ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... May 3, 2016   BIOTRONIK will be ... care beyond the implant at the Heart Rhythm Society,s ... San Francisco . ... highest quality of patient care and satisfaction possible. Part ... each and every tomorrow," said Marlou Janssen , ...
(Date:5/3/2016)... Pharmaceutical giant Johnson & Johnson ... woman who says its talc-based powder products caused ovarian ... $5 million in compensatory damages and $50 million ... ) , This is the second ... February, the same court awarded $72 million to the ...
(Date:5/3/2016)... 2016  Specialty Silicone Fabricators is offering teachers ... a cleanroom works. The free visual aid provides ... technology. Chris Mazelin , ... SSF enthusiastically supports the Science, Technology, Engineering and ... next generation of innovators. We want to provide ...
Breaking Medicine Technology: